Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Morphotek’s Busy Year Continues With NCI Collaboration On Prostate Cancer Antibody

This article was originally published in PharmAsia News

Executive Summary

Eisai-subsidiary Morphotek signed an agreement with the U.S. National Cancer Institute Aug. 13 under which the firm will use its proprietary Morphodoma technology to develop novel human monoclonal antibodies as potential therapies for prostate cancer. The deal gives the biotech rights to antibodies for a novel antigen identified by NCI researchers

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts